Physician profile
Ryan S Kim
NPI 1497384341
$3,724.74
in general payments reported to CMS, 2019-2025
14 companies · $2,475 in 2025
The $2,475 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $262 · 2024: $987 · 2025: $2,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775 · Consulting Fee: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.74 |
| Consulting Fee | $950.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.70 | 2024-2025 | |
| Alcon Vision LLC | $910.47 | 2024-2025 | Clareon, Clareon Panoptix Pro, Acrysof Iq Vivity |
| Sight Sciences, INC. | $347.37 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Amgen INC. | $281.38 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $262.30 | 2023 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator, Lipiflow System Activator II (Disposable |
| Biotissue Holdings INC. | $186.91 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $119.54 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $75.55 | 2024-2025 | Idose |
| Bausch & Lomb Americas INC. | $39.42 | 2025 | Xiidra, Miebo |
| Harrow Eye, LLC | $34.49 | 2024-2025 | Vevye |
| Dompe US, INC. | $21.52 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $20.08 | 2024 | Ryzumvi, Tyrvaya |
| Sun Pharmaceutical Industries INC. | $17.79 | 2025 | |
| Rxsight INC | $14.22 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.